Turn Therapeutics

Turning The Corner On Antimicrobial Resistance

About this Event

Founded by Bradley Burnam after he contracted a recurring, highly-resistant Klebsiella infection that led to 20+ surgeries, Turn Therapeutics has developed and obtained three FDA clearances for a breakthrough product employing a multi-patented delivery technology that embeds suspended, non-diluted nanodroplets within oil-based carriers to deliver active ingredients through skin, nails, and mucous membranes.

Turn’s delivery technology is also very flexible. Using it, Turn developed a product that is the subject of a $70M licensing agreement with MIMEDX (NASDAQ: MDXG) which not only stands to generate significant revenue for the company, but also showcases the commercial viability and credibility of the technology and corporation after extensive diligence.

In addition, Turn is working on two other programs based on its unique platform technology: MRSA Decolonization and Onychomycosis, with a combined global TAM of $11.1B. They also have research and development partnerships with a global top-10 pharmaceutical company to employ Turn’s technology for the benefit of neglected tropical disease targets, as well as another global pharma to embed its vaccines in Turn’s delivery system to create thermostable, intranasally-delivered vaccines. This second partnership stands to produce data by or within Q2, 2024 and could move the company toward another strategic partnership with some haste given the potential societal and financial impact.

Watch the webinar with Turn Founder and CEO, Bradley Burnam, to hear hear the remarkable story behind the founding of Turn, and more about its promising future.

Hosted by Steven Saltzstein. CEO, Force Family Office

Video On Demand

– Recorded

January 31


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.